Summary of protocol
EudraCT number: 2009-014415-12

Title	A multicentre, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to determine the effect of mepolizumab on exacerbation rates in subjects with severe uncontrolled refractory asthma.
Primary endpoint	Worsening of asthma requiring use of oral/systemic corticosteroids and /or hospitalization and /or ED visits.
Study design	Randomized, double-blind, placebo-controlled, multicentre study
Number of patients	6 - 12 patients
Main inclusion criteria	1. The subject aged 18 - 65 years. 2. With a minimum weight of 45 kg. 3. And with clinical features of severe refractory asthma for ≥ 12 month prior to Visit 1. 4. Treated twice a year with systemic corticosteroids.
Exclusion criteria	1. Current smokers. 2. The subject treated with Omalizumab within the last 6 months. 3. The subject suffering from severe acute or chronic diseases
Treatment	Mepolizumab (SB 240563), anti-IL-5 mAb
Sponsor	GlaxoSmithKline GmbH & Co. KG